Table 7.
Detailed characteristics of the studied cohort.
| All (n = 397) |
≤55 Years Old (n = 109) | 60–70 Years Old (n = 253) | 70> Years Old (n = 35) | ||||
|---|---|---|---|---|---|---|---|
| Early (n = 53) |
Late (n = 56) |
Early (n = 84) |
Late (n = 169) |
Early (n = 13) |
Late (n = 22) |
||
| Age | 63 (41–78) | 51 | 53 | 64 | 65 | 72 | 72 |
| -median | |||||||
| Race | |||||||
| -Asian | 2 | - | 1 | - | 1 | - | - |
| -Black or African American | 6 | 1 | 2 | - | 2 | 1 | - |
| -White | 125 | 15 | 18 | 32 | 49 | 7 | 4 |
| -NA | 264 | 37 | 35 | 52 | 117 | 5 | 18 |
| Tumor status | 250 | 41 | 37 | 63 | 88 | 11 | 10 |
| -tumor free | 65 | 3 | 12 | 3 | 41 | - | 6 |
| -with tumor | 82 | 9 | 7 | 18 | 40 | 2 | 6 |
| -NA | |||||||
| Vital status | 391 | 53 | 54 | 83 | 166 | 13 | 22 |
| -alive | 6 | - | 2 | 1 | 3 | - | - |
| -dead | |||||||
| Adjuvant radiation treatment | 191 | 30 | 23 | 42 | 79 | 5 | 12 |
| -no | 32 | - | 5 | 1 | 26 | - | - |
| -yes | 174 | 23 | 28 | 31 | 64 | 8 | 10 |
| -NA | |||||||
| Treatment outcome of first course | 124 | 18 | 14 | 30 | 49 | 5 | 8 |
| -complete remission/response | 23 | - | 4 | - | 14 | - | 4 |
| -partial remission/response | 19 | - | - | 2 | 17 | - | - |
| -stable disease | 12 | - | 4 | - | 8 | - | - |
| -progressive disease | 219 | 35 | 34 | 50 | 81 | 8 | 10 |
| -NA | |||||||
| Laterality | 343 | 43 | 52 | 71 | 146 | 11 | 20 |
| -bilateral | 17 | 3 | 2 | 1 | 10 | 1 | - |
| -left | 31 | 6 | 1 | 12 | 9 | 1 | 2 |
| -right | 6 | 1 | 1 | - | 4 | - | - |
| -NA | |||||||
| Residual tumor | 254 | 43 | 28 | 71 | 92 | 10 | 10 |
| -R0 | 117 | 7 | 22 | 7 | 68 | 2 | 11 |
| -R1 | 4 | 1 | - | 1 | 1 | - | 1 |
| -R2 | 12 | - | 2 | 3 | 7 | - | - |
| -RX | 10 | 2 | 4 | 2 | 1 | 1 | - |
| -NA | |||||||
| New tumor event | 195 | 34 | 25 | 48 | 73 | 5 | 10 |
| -no | 53 | - | 9 | 4 | 37 | - | 3 |
| -yes | 148 | 19 | 22 | 32 | 59 | 8 | 9 |
| -NA | |||||||
| Targeted molecular therapy | 21 | 43 | 84 | 5 | 10 | ||
| -no | 193 | 30 | 6 | - | 21 | - | 2 |
| -yes | 29 | - | 29 | 41 | 64 | 8 | 10 |
| -NA | 175 | 23 | |||||
| Stage | |||||||
| T [clinical/pathologic] | |||||||
| -T1a | 1/- | - | - | - | 1/- | - | - |
| -T1b | 1/- | - | - | - | 1/- | - | - |
| -T1c | 141/- | 30/- | 17/- | 45/- | 43/- | 3/- | 3/- |
| -T2 | 11/- | 2/- | 1/- | 2/- | 3/- | - | 3/- |
| -T2a | 44/12 | 6/4 | 7/- | 9/6 | 18/- | 1/2 | 3/- |
| -T2b | 45/11 | 3/4 | 9/- | 7/6 | 22/- | 1/1 | 3/- |
| -T2c | 37/128 | 6/45 | 4/2 | 8/71 | 18/- | 1/10 | - |
| -T3a | 28/127 | - | 7/28 | 2/- | 15/91 | - | 4/8 |
| -T3b | 14/110 | - | 3/25 | - | 10/73 | - | 1/12 |
| -T4 | 8-Feb | - | 1/1 | - | 1/5 | - | -/2 |
| -NA | 73/1 | 6/- | 7/- | 11/1 | 37/- | 7/- | 5/- |
| N [pathologic] | |||||||
| -N0 | 282 | 35 | 34 | 68 | 121 | 10 | 14 |
| -N1 | 60 | - | 16 | - | 37 | - | 7 |
| -NA | 55 | 18 | 6 | 16 | 11 | 3 | 1 |
| M [clinical] | |||||||
| -M0 | 362 | 46 | 53 | 80 | 152 | 10 | 21 |
| -M1a | 1 | - | - | - | 1 | - | - |
| -M1c | 1 | - | 1 | - | - | - | - |
| -NA | 33 | 7 | 2 | 4 | 16 | 3 | 1 |
| Zone of origin | |||||||
| -central zone | 4 | 1 | - | 1 | 2 | - | - |
| -overlapping/multiple zones | 98 | 7 | 13 | 10 | 55 | 1 | 12 |
| -peripheral zone | 112 | 15 | 13 | 25 | 52 | 3 | 4 |
| -transition zone | 6 | 1 | 3 | 1 | - | - | 1 |
| -NA | 177 | 29 | 27 | 47 | 60 | 9 | 5 |
| Gleason score | |||||||
| -6 | 33 | 14 | 1 | 8 | 6 | 3 | 1 |
| -7 | 203 | 35 | 29 | 63 | 62 | 7 | 7 |
| -8 | 49 | 4 | 8 | 6 | 26 | 3 | 2 |
| -9 | 109 | - | 17 | 7 | 73 | - | 12 |
| -10 | 3 | - | 1 | - | 2 | - | - |
| Primary pattern | |||||||
| -2 | 1 | - | - | - | - | - | 1 |
| -3 | 149 | 44 | 14 | 50 | 29 | 8 | 4 |
| -4 | 208 | 9 | 34 | 33 | 116 | 5 | 11 |
| -5 | 39 | - | 8 | 1 | 24 | - | 6 |
| Secondary pattern | |||||||
| -3 | 127 | 21 | 18 | 30 | 50 | 5 | 3 |
| -4 | 185 | 30 | 26 | 47 | 61 | 8 | 13 |
| -5 | 85 | 2 | 12 | 7 | 58 | - | 6 |
| Biochemical recurrence indicator | |||||||
| -no | 295 | 43 | 41 | 68 | 114 | 10 | 19 |
| -yes | 46 | 1 | 8 | 4 | 33 | - | - |
| -NA | 56 | 9 | 7 | 12 | 22 | 3 | 3 |